A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema. [PDF]
Front PharmacolZhai G, Ren X, Xu B, Mi D.
europepmc +1 more source
Off-patent transgenic events : challenges and opportunities for new actors and markets in agriculture [PDF]
, 2018 Dumont, Philippe +4 more
core +2 more sources
Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan. [PDF]
J Pharm Policy PractMamiya H, Fukasawa T, Kawakami K.
europepmc +1 more source
Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. [PDF]
Int J Technol Assess Health CareHussain A, Fairbairn R, Khan SK.
europepmc +1 more source
Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap (XM17), Comparability with Gonal-f, and Performance/Consistency [PDF]
, 2017 core +1 more source
Switching From Intravitreal Ranibizumab (Lucentis) to Biosimilar Ranibizumab (Ongavia) Injections: Insights From a Tertiary Care Eye Centre. [PDF]
CureusSourla E, Zaheer N, Chavan R.
europepmc +1 more source
Performance evaluation of an adalimumab biosimilar autoinjector and its reference device: comparative use human factors study in patients with rheumatoid arthritis and juvenile idiopathic arthritis. [PDF]
Drug DelivMoses K S +1 more
europepmc +1 more source
Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials. [PDF]
Clin Exp MedShakibaei F +3 more
europepmc +1 more source
Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review. [PDF]
Endocrinol Diabetes MetabHindley B +4 more
europepmc +1 more source